Learn languages naturally with fresh, real content!

Popular Topics
Explore By Region
A Delaware judge dismissed Eli Lilly’s lawsuit against Strive Pharmacy over compounded tirzepatide due to lack of jurisdiction, allowing a potential refiling in Arizona.
A Delaware judge dismissed Eli Lilly’s lawsuit against Strive Pharmacy over its compounded tirzepatide, citing lack of personal jurisdiction, while acknowledging compounded drugs provide critical access for patients with unique needs or during shortages.
The decision, without prejudice, allows Lilly to refile in Arizona.
Compounded GLP-1s cost significantly less than brand-name versions but face insurance restrictions.
This follows a similar dismissal against another telehealth company, reflecting a growing judicial recognition of compounding pharmacies as legitimate providers.
Meanwhile, patients increasingly seek unapproved, unregulated versions of GLP-1 drugs due to high costs and limited access, raising public health concerns over counterfeit or unsafe products.
Un juez de Delaware desestimó la demanda de Eli Lilly contra Strive Pharmacy por tirzepatida compuesta debido a la falta de jurisdicción, lo que permite una posible nueva presentación en Arizona.